MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
GNPX - Genprex Inc
$1.58
-0.07(-4.24%)6:00:00 PM 11/26/2021
Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company's lead product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex also block mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    11/16/2021GNPX
    Genprex to Present in November CEO Roadshow Webinar

    AUSTIN, Texas, November 16, 2021--Genprex's CEO will present on November 17 at 11 a.m. ET with CEO Roadshow.

    09/30/2021GNPX
    JinkoSolar Provides Updates on Jinko Solar Co., Ltd.'s Proposed IPO in China

    JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, provided updates on the status of the proposed initial public offering ("STAR Market IPO") and listing of the shares of its principal operating subsidiary, Jinko Solar Co., Ltd. ("Jiangxi Jinko"), on the Shanghai Stock Exchange's Sci-Tech innovation board (the "STAR Market").

    09/29/2021GNPX
    JinkoSolar Awarded "Top Brand PV USA 2021" by EUPD Research

    JinkoSolar Holding Co., Ltd. (the "Company," or "JinkoSolar") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that it was awarded the 'Top Brand PV USA' seal by EUPD Research.

    09/28/2021GNPX
    Genprex Inc. Strengthens Management Team with Strategic Appointments

    Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of chief medical officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of chief manufacturing and technology officer. According to the update, Drs. Berger and Kumar will report to Rodney Varner, c

    09/28/2021GNPX
    Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

    AUSTIN, Texas, September 28, 2021--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer.

    09/27/2021GNPX
    JinkoSolar's New 7GW Ingot/Wafer Facility in Vietnam to Strengthen the Sustainability of its Global Supply Chain by 2022

    JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that the Company is investing $500 million to build a monocrystalline ingot and wafer manufacturing facility in Quảng Ninh Province, Vietnam. JinkoSolar has begun to work on the facility, which is expected to have an annual capacity of 7GW to support its existing overseas production facilities. JinkoSolar is committed to ensurin

    09/24/2021GNPX
    JinkoSolar's Subsidiary Jinko Solar Co., Ltd. Provides Preliminary Estimates of Revenue and Net Income for the First Nine Months of 2021

    JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, is in the process of applying for an initial public offering ("IPO") of its principal operating subsidiary, Jinko Solar Co., Ltd. ("Jiangxi Jinko"), on the Shanghai Stock Exchange's Sci-Tech innovation board.

    09/20/2021GNPX
    Genprex to Participate in September Investor Conferences

    AUSTIN, Texas, September 20, 2021--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be participating in two investor conferences in September 2021.

    07/20/2021GNPX
    Genprex to Participate in a Monthly CEO Roadshow Webinar Series

    AUSTIN, Texas, July 20, 2021--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be participating in a webinar series with CEO Roadshow to provide a company overview to investors on a monthly basis from July through September 2021.